Protocol Ledger

NCT05482971 · Phase II · ACTIVE NOT RECRUITING

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Interventional Phase II clinical trial protocol NCT05482971 sponsored by PharmaEssentia in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-29 Enrollment: 91 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05482971
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)91 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05482971
Protocol FieldVerified Registry Value
NCT IdentifierNCT05482971
Consolidated Lead SponsorPharmaEssentia
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment91 participants (ACTUAL)
Registered Start Date2022-09-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI